Clinical trial · Interventional
Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute
NCT02036489CI-TRIAL-00043826completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Understand the dynamics of elimination of MRD in adult patients with standard-risk LAL treated with a pediatric protocol.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphobkastic Leukemia | — | UNRESOLVED | — |
Interventions
Interventions (11)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ARA-C | Drug | Cytarabine | ALIAS |
| Ciclophosphamide | Drug | — | UNRESOLVED |
| Daunorubicin | Drug | Daunorubicin | ALIAS |
| Dexametasone | Drug | — | UNRESOLVED |
| Hidrocortisone | Drug | — | UNRESOLVED |
| L-asparaginase | Drug | Asparaginase | ALIAS |
| Mercaptopurine | Drug | Mercaptopurine | ALIAS |
| Metotrexate | Drug | — | UNRESOLVED |
| Prednisone | Drug |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Induction and consolidation treatment
- interventionNames
- Drug: Vincristine
- Drug: Daunorubicin
- Drug: Prednisone
- Drug: L-asparaginase
- Drug: Ciclophosphamide
- Drug: Metotrexate
- Drug: ARA-C
- Drug: Hidrocortisone
- Drug: Mercaptopurine
- Drug: VP-16
- Drug: Dexametasone
Primary outcomes (1)
- measure
- Efficacy of treatment in adulta with standard risk acute lymphoblastic leukemia
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
Show eligibility criteria text
Inclusion Criteria: Adults (age\> 15 years) with ALL standard risk previously untreated. The LAL standard risk is defined by all of the following criteria: * Age less than 30 years * WBC \<25x109 / L * Absence of cytogenetic alterations that misbehave forecast or t (9, 22) or demonstration of BCR-ABL rearrangement or alterations in 11q23, or demonstration ALL1-AF4 rearrangement (MLL) Exclusion Criteria: LAL L3 type mature phenotype B (sIg +) or with cytogenetic abnormalities characteristic of Burkitt LAL (t \[8, 14\], t \[2, 8\], t \[8, 22\]). For these patients have the BURKIMAB study. * LAL Ph (BCR-ABL) positive. These patients should be treated with imatinib associated with chemotherapy. * Biphenotypic acute leukemias and bilinear. For these patients treatment is recommended LAM own guidelines. * Acute undifferentiated leukemias. For these patients treatment is recommended LAM own guidelines. * Patients with a history of coronary artery disease, valvular or hypertensive heart disease. * Patients with chronic liver disease. * Patients with chronic respiratory failure. * Renal failure not due to the LAL. * Severe neurological disorders, not due to the LAL. * General State concerned (grades 3 and 4 WHO scale), not attributable to the LAL.
References
Publications (0)
Data not yet available
No reference posted for this study.